These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 22531234)

  • 81. Effectiveness of Palivizumab Against Respiratory Syncytial Virus Hospitalization Among Preterm Infants in a Setting With Year-Round Circulation.
    Yeo KT; Yung CF; Khoo PC; Saffari SE; Sng JSP; How MS; Quek BH
    J Infect Dis; 2021 Jul; 224(2):279-287. PubMed ID: 33274362
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Incidence, risk factors and hospital burden in children under five years of age hospitalised with respiratory syncytial virus infections.
    Svensson C; Berg K; Sigurs N; Trollfors B
    Acta Paediatr; 2015 Sep; 104(9):922-6. PubMed ID: 26036725
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Effect of Prophylactic Palivizumab on Admission Due to Respiratory Syncytial Virus Infection in Former Very Low Birth Weight Infants with Bronchopulmonary Dysplasia.
    Han YM; Seo HJ; Choi SH; Jung YJ; Ahn SY; Yoo HS; Sung SI; Shim JW; Lee YK; Ko SY; Shin SM; Hwang JH; Lee JH; Choi BM; Kim ES; Jeon JH; Kim SS; Chang YS; Park WS
    J Korean Med Sci; 2015 Jul; 30(7):924-31. PubMed ID: 26130956
    [TBL] [Abstract][Full Text] [Related]  

  • 84. A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29-35 weeks' gestational age.
    Keary IP; Ravasio R; Fullarton JR; Manzoni P; Lanari M; Paes BA; Carbonell-Estrany X; Baraldi E; Tarride JÉ; Rodgers-Gray B
    PLoS One; 2023; 18(8):e0289828. PubMed ID: 37561741
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Increased risk for respiratory syncytial virus-associated, community-acquired alveolar pneumonia in infants born at 31-36 weeks of gestation.
    Greenberg D; Dagan R; Shany E; Bar-Ziv J; Givon-Lavi N
    Pediatr Infect Dis J; 2014 Apr; 33(4):381-6. PubMed ID: 24145171
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Respiratory syncytial virus infection in 406 hospitalized premature infants: results from a prospective German multicentre database.
    Simon A; Ammann RA; Wilkesmann A; Eis-Hübinger AM; Schildgen O; Weimann E; Peltner HU; Seiffert P; Süss-Grafeo A; Groothuis JR; Liese J; Pallacks R; Müller A;
    Eur J Pediatr; 2007 Dec; 166(12):1273-83. PubMed ID: 17943313
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Comparison of the timing of initial prophylactic palivizumab dosing on hospitalization of neonates for respiratory syncytial virus.
    Ohler KH; Pham JT
    Am J Health Syst Pharm; 2013 Aug; 70(15):1342-6. PubMed ID: 23867491
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Respiratory disorders and hospitalization rates during the second RSV season in preterm infants who received palivizumab prophylaxis during their first RSV season.
    Fanos V; Scarcella A; Puddu M; Gallini F; Tuminelli F; Bragetti P; Gallina MR; Quartulli L; Benincori N; Citro G; Via LD; Barera G; DI Luzio Paparatti U; Merolla R; Romano GV; Guida G; Silvestri M; Rossi GA
    J Chemother; 2009 Jun; 21(3):302-10. PubMed ID: 19567351
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Rehospitalization for respiratory syncytial virus among premature infants.
    Joffe S; Escobar GJ; Black SB; Armstrong MA; Lieu TA
    Pediatrics; 1999 Oct; 104(4 Pt 1):894-9. PubMed ID: 10506231
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants.
    Yoshihara S; Kusuda S; Mochizuki H; Okada K; Nishima S; Simões EA;
    Pediatrics; 2013 Nov; 132(5):811-8. PubMed ID: 24127479
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Appropriateness of age thresholds for respiratory syncytial virus immunoprophylaxis in moderate-preterm infants: a cohort study.
    Winterstein AG; Knox CA; Kubilis P; Hampp C
    JAMA Pediatr; 2013 Dec; 167(12):1118-24. PubMed ID: 24126903
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Children hospitalized with respiratory syncytial virus infection in Saskatchewan pediatric tertiary care centers, 2002-2005.
    Kurji A; Tan B; Bodani J; Janzen B; McConnell A; Bodani R; Rajakumar D; Sharma A; Sankaran K
    Zhongguo Dang Dai Er Ke Za Zhi; 2014 Oct; 16(10):1005-13. PubMed ID: 25344181
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29-32 weeks.
    Resch B; Gusenleitner W; Müller WD; Haas J
    Eur J Clin Microbiol Infect Dis; 2006 Feb; 25(2):120-2. PubMed ID: 16491302
    [No Abstract]   [Full Text] [Related]  

  • 94. Palivizumab administration in preterm infants in France: EPIPAGE-2 cohort study.
    Torchin H; Rousseau J; Marchand-Martin L; Truffert P; Jarreau PH; Ancel PY
    Arch Pediatr; 2018 Feb; 25(2):89-94. PubMed ID: 29395887
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Ethical considerations and rationale of the MAKI trial: a multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks.
    Blanken M; Rovers M; Sanders E; Bont L
    Contemp Clin Trials; 2012 Nov; 33(6):1287-92. PubMed ID: 22820319
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Cost-effectiveness of palivizumab in New Zealand.
    Vogel AM; McKinlay MJ; Ashton T; Lennon DR; Harding JE; Pinnock R; Graham D; Grimwood K; Pattemore PK; Schousboe M
    J Paediatr Child Health; 2002 Aug; 38(4):352-7. PubMed ID: 12173995
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Prolonged seasonality of respiratory syncytial virus infection among preterm infants in a subtropical climate.
    Hsu CH; Lin CY; Chi H; Chang JH; Hung HY; Kao HA; Peng CC; Jim WT
    PLoS One; 2014; 9(10):e110166. PubMed ID: 25333346
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Impact of palivizumab on admission to the ICU for respiratory syncytial virus bronchiolitis: a national survey.
    Prais D; Danino D; Schonfeld T; Amir J
    Chest; 2005 Oct; 128(4):2765-71. PubMed ID: 16236953
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Lower respiratory tract illness and RSV prophylaxis in very premature infants.
    Lacaze-Masmonteil T; Truffert P; Pinquier D; Daoud P; Goldfarb G; Vicaut E; Fauroux B
    Arch Dis Child; 2004 Jun; 89(6):562-7. PubMed ID: 15155404
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States.
    Weiner LB; Masaquel AS; Polak MJ; Mahadevia PJ
    J Med Econ; 2012; 15(5):997-1018. PubMed ID: 22435648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.